These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18800763)

  • 1. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.
    Heerding DA; Rhodes N; Leber JD; Clark TJ; Keenan RM; Lafrance LV; Li M; Safonov IG; Takata DT; Venslavsky JW; Yamashita DS; Choudhry AE; Copeland RA; Lai Z; Schaber MD; Tummino PJ; Strum SL; Wood ER; Duckett DR; Eberwein D; Knick VB; Lansing TJ; McConnell RT; Zhang S; Minthorn EA; Concha NO; Warren GL; Kumar R
    J Med Chem; 2008 Sep; 51(18):5663-79. PubMed ID: 18800763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
    Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminofurazans as potent inhibitors of AKT kinase.
    Rouse MB; Seefeld MA; Leber JD; McNulty KC; Sun L; Miller WH; Zhang S; Minthorn EA; Concha NO; Choudhry AE; Schaber MD; Heerding DA
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1508-11. PubMed ID: 19179070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism and management of AKT inhibitor-induced hyperglycemia.
    Crouthamel MC; Kahana JA; Korenchuk S; Zhang SY; Sundaresan G; Eberwein DJ; Brown KK; Kumar R
    Clin Cancer Res; 2009 Jan; 15(1):217-25. PubMed ID: 19118049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
    Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
    Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
    J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
    J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
    Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold.
    Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL
    Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
    Hu C; Solomon VR; Ulibarri G; Lee H
    Bioorg Med Chem; 2008 Sep; 16(17):7888-93. PubMed ID: 18691894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors.
    Seefeld MA; Rouse MB; McNulty KC; Sun L; Wang J; Yamashita DS; Luengo JI; Zhang S; Minthorn EA; Concha NO; Heerding DA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2244-8. PubMed ID: 19285393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
    Li Q; Li T; Zhu GD; Gong J; Claibone A; Dalton C; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Bauch JL; Marsh KC; Bouska JJ; Arries S; De Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1679-85. PubMed ID: 16403626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
    Bencsik JR; Xiao D; Blake JF; Kallan NC; Mitchell IS; Spencer KL; Xu R; Gloor SL; Martinson M; Risom T; Woessner RD; Dizon F; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ; Prior WW; Murray LJ
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7037-41. PubMed ID: 20971641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
    Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure based optimization of novel Akt inhibitors.
    Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.